MY142283A - Diagnosis and treatment of cancers and other conditions - Google Patents
Diagnosis and treatment of cancers and other conditionsInfo
- Publication number
- MY142283A MY142283A MYPI20023310A MYPI20023310A MY142283A MY 142283 A MY142283 A MY 142283A MY PI20023310 A MYPI20023310 A MY PI20023310A MY PI20023310 A MYPI20023310 A MY PI20023310A MY 142283 A MY142283 A MY 142283A
- Authority
- MY
- Malaysia
- Prior art keywords
- probe
- receptors
- functional
- treatment
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR7431A AUPR743101A0 (en) | 2001-09-03 | 2001-09-03 | A cancer therapeutic |
AUPR7430A AUPR743001A0 (en) | 2001-09-03 | 2001-09-03 | Diagnosis and treatment of irritable bowel syndrome |
PCT/AU2002/000061 WO2002057306A1 (fr) | 2001-01-17 | 2002-01-17 | Anticorps du recepteur p2x7 non fonctionnel, diagnostic et traitement de cancers et autres etats pathologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MY142283A true MY142283A (en) | 2010-11-15 |
Family
ID=41706691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20023310A MY142283A (en) | 2001-09-03 | 2002-09-04 | Diagnosis and treatment of cancers and other conditions |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP4467973B2 (fr) |
CN (2) | CN100497386C (fr) |
AU (1) | AU2002322192B2 (fr) |
CA (1) | CA2459348C (fr) |
MY (1) | MY142283A (fr) |
NZ (2) | NZ549019A (fr) |
TW (1) | TWI329648B (fr) |
WO (1) | WO2003020762A1 (fr) |
ZA (1) | ZA200402630B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1360203E (pt) | 2001-01-17 | 2009-04-03 | Intreat Pty Ltd | Anticorpos de receptor p2x7 não funcional para diagnóstico e tratamento de cancros e outros estados |
AU2003298003A1 (en) * | 2002-12-05 | 2004-06-30 | Kla-Tencor Technologies Corporation | Apparatus and methods for detecting overlay errors using scatterometry |
WO2004090097A2 (fr) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide codant un nouveau variant d'epissage p2x7 humain appele hbmyp2x7v |
US8124730B1 (en) | 2004-04-02 | 2012-02-28 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v |
US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
WO2008043146A1 (fr) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Anticorps contre le récepteur p2x7 non fonctionnel |
AU2007306924A1 (en) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Hybridomas producing antibodies against non functional P2X7 receptor |
CA2737126C (fr) * | 2007-09-14 | 2018-05-01 | Biosceptre International Limited | Nouveaux epitopes p2x7 |
AU2013238152B2 (en) * | 2007-09-14 | 2015-09-24 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
US8293491B2 (en) | 2007-09-14 | 2012-10-23 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
AU2009266430B2 (en) | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
CN101469352B (zh) * | 2008-08-29 | 2011-12-21 | 苏州福英基因科技有限公司 | 一种早期子宫癌原位杂交检测试剂盒 |
EP2966090B1 (fr) | 2009-08-20 | 2018-10-10 | Biosceptre (Aust) Pty Ltd | Anticorps du récepteur anti p2x7 et fragments de ceux-ci |
WO2011075789A1 (fr) | 2009-12-24 | 2011-06-30 | Biosceptre International Limited | Anticorps dirigés contre des récepteurs p2x7 oligomères non fonctionnels |
CN106310245A (zh) | 2010-09-10 | 2017-01-11 | 生物权威(澳大利亚)有限责任公司 | 陪伴动物治疗 |
AU2012278921B2 (en) * | 2011-07-01 | 2016-11-10 | Biosceptre International Limited | Combination therapy |
EP2990800A1 (fr) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin comme marqueur pronostique pour l'insuffisance cardiaque |
EP3347474B1 (fr) | 2015-09-11 | 2020-11-04 | Biosceptre (UK) Limited | Récepteurs d'antigènes chimériques et leurs utilisations |
AU2017346936B2 (en) * | 2016-10-21 | 2022-10-06 | Biosceptre (Aust) Pty Ltd | Cytotoxic particles |
CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133434A (en) * | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
PT1360203E (pt) * | 2001-01-17 | 2009-04-03 | Intreat Pty Ltd | Anticorpos de receptor p2x7 não funcional para diagnóstico e tratamento de cancros e outros estados |
-
2002
- 2002-09-03 NZ NZ549019A patent/NZ549019A/en not_active IP Right Cessation
- 2002-09-03 CN CNB028214331A patent/CN100497386C/zh not_active Expired - Lifetime
- 2002-09-03 CA CA2459348A patent/CA2459348C/fr not_active Expired - Lifetime
- 2002-09-03 AU AU2002322192A patent/AU2002322192B2/en not_active Expired
- 2002-09-03 WO PCT/AU2002/001204 patent/WO2003020762A1/fr active Application Filing
- 2002-09-03 JP JP2003525032A patent/JP4467973B2/ja not_active Expired - Lifetime
- 2002-09-03 CN CN2008102142942A patent/CN101445555B/zh not_active Expired - Lifetime
- 2002-09-03 TW TW091120122A patent/TWI329648B/zh not_active IP Right Cessation
- 2002-09-03 NZ NZ565994A patent/NZ565994A/en not_active IP Right Cessation
- 2002-09-04 MY MYPI20023310A patent/MY142283A/en unknown
-
2004
- 2004-04-02 ZA ZA2004/02630A patent/ZA200402630B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003020762A1 (fr) | 2003-03-13 |
NZ549019A (en) | 2008-05-30 |
CN100497386C (zh) | 2009-06-10 |
CA2459348A1 (fr) | 2003-03-13 |
NZ565994A (en) | 2010-02-26 |
JP2005513416A (ja) | 2005-05-12 |
CN1625565A (zh) | 2005-06-08 |
AU2002322192B2 (en) | 2008-05-01 |
ZA200402630B (en) | 2005-06-29 |
JP4467973B2 (ja) | 2010-05-26 |
CA2459348C (fr) | 2013-06-18 |
CN101445555B (zh) | 2013-07-03 |
TWI329648B (en) | 2010-09-01 |
CN101445555A (zh) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY158262A (en) | Diagnosis and treatments of cancers and other conditions | |
MY142283A (en) | Diagnosis and treatment of cancers and other conditions | |
KR100711046B1 (ko) | 대장암에 대한 마커로서의 니코틴아미드n―메틸트랜스퍼라아제의 용도 | |
ATE461449T1 (de) | Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben | |
ATE337011T1 (de) | Modifizierte psma-liganden und deren verwendung | |
UA90082C2 (ru) | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 | |
NO20082559L (no) | Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer | |
HUP0202532A2 (hu) | Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása | |
ZA200508390B (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
EP2021794B8 (fr) | Utilisation de la protéine s100a 12 en tant que marqueur du cancer du côlon et du rectum | |
DK1692181T3 (da) | Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin | |
WO2004022006A3 (fr) | Procede de diagnostic du cancer du col de l'uterus | |
WO2008060376A3 (fr) | Algorithmes pour modèles multivariants pour combiner un panel de biomarqueurs afin d'évaluer le risque de développer un cancer ovarien | |
DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome | |
WO2004074325A3 (fr) | Compositions et methodes de detection et de traitement des cancers a deficience de methylthioadenosine phosphorylase | |
DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
MXPA04004018A (es) | Metodos de separacion por exclusion para toxicidad de compuestos de prueba. | |
NO20022441L (no) | Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse | |
WO2003104761A3 (fr) | Mesure de peptides de melanocortine et utilisations correspondantes | |
HUP0101285A2 (hu) | Eljárások és készítmények a hepatóma diagnosztizálására | |
BR0308117A (pt) | Dìmeros de avidina eficazes em aumentar a concentração de biotina radioativa em radioimunoterapia pré-direcionada | |
EP0563244A4 (en) | Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis | |
DE60127935D1 (de) | Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie | |
BRPI0415562A (pt) | reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma | |
DE50006083D1 (de) | Labormässige untersuchung einer körperflüssigkeits- oder gewebeprobe |